

AGENDA
U.S. Environmental Protection Agency
Science Advisory Board
Chemical Assessment Advisory Committee (CAAC)
Augmented for the Review of *Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)*
Public Meeting

Milken Institute School of Public Health
Convening Center Room, George Washington University
950 New Hampshire Avenue NW, Washington, DC 20052

December 12 -14, 2016

Purpose: To peer review the EPA's *Toxicological Review of Hexahydro-1,3,5-trinitro-1,3,5-triazine (External Review Draft, September 2016)*.

Monday, December 12, 2016

9:00 a.m.	Convene Meeting	Dr. Diana Wong Designated Federal Officer EPA SAB Staff Office
9:05 a.m.	Welcoming Remarks	Mr. Christopher Zarba Director, SAB Staff Office
9:15 a.m.	Introduction of CAAC Augmented RDX Review Panel and Review of Agenda	Dr. Kenneth Ramos, Chair SAB CAAC Augmented for RDX
9:30 a.m.	EPA Presentations	Dr. Vincent Cogliano Director, IRIS Program EPA National Center for Environmental Assessment (NCEA) Dr. Louis D'Amico Assessment Manager EPA NCEA
10:15 a.m.	Break	
10:30 a.m.	Public Comments	Registered Public Speakers
10:45 a.m.	Review of Charge Questions	Dr. Ramos and Augmented CAAC Members

11:00 a.m.	Discussion of Response to Charge Questions	Writing Groups*:
	<ul style="list-style-type: none"> • Charge Question #1 – Literature Search/Study Selection and Evaluation 	Drs. <u>Melanie Marty</u> , <u>George Cobb</u> and All Panel Members
12:00 p.m.	Lunch	
1:00 p.m.	<ul style="list-style-type: none"> • Charge Question #2 – Toxicokinetic modeling 	
	2a Model evaluation	Drs. <u>Hugh Barton</u> , James Bruckner, <u>Marilyn Morris</u>
	2b Selection of dose metric	Drs. <u>Hugh Barton</u> , James Bruckner, <u>Marilyn Morris</u>
	2c Model uncertainties	Drs. <u>Hugh Barton</u> , James Bruckner, <u>Marilyn Morris</u>
2:30 p.m.	Break	
2:45 p.m.	<ul style="list-style-type: none"> • Charge Question #3 – Hazard Identification and dose-response assessment 	
	3a <u>Nervous system effects</u>	
	3a(i) Nervous system hazard	Drs. <u>Stephen Lasley</u> , <u>Victoria Persky</u> , Isaac Pessah, Samba Reddy
	3a(ii) Nervous system specific toxicity values	Drs. <u>Stephen Lasley</u> , <u>Isaac Pessah</u> , Samba Reddy
	3a(iii) POD for nervous system endpoints	Drs. <u>Hugh Barton</u> , Jacqueline Hughes-Oliver, Stephen Lesley, Marilyn Morris, Isaac Pessah, <u>Ken Portier</u> , Sam Reddy, Alan Stern
	3a(iv) Uncertainty factors for nervous system endpoints	Drs. Joanne English, <u>Melanie Marty</u> , <u>Alan Stern</u>
	3a(v) Nervous system specific Reference dose	Drs. <u>Stephen Lasley</u> , <u>Isaac Pessah</u> , Samba Reddy

* Lead discussants are denoted by underlines

4:15 p.m.	3b <u>Kidney and other urogenital system effects</u>	
	3b(i) Kidney and other urogenital system hazard	Drs. <u>Maarten Bosland</u> , <u>Lawrence Lash</u> , Victoria Persky, Thomas Rosol
	3b(ii) Kidney and other urogenital system-specific toxicity value	Drs. <u>Maarten Bosland</u> , Lawrence Lash, <u>Thomas Rosol</u>

5:30 p.m. **Recess**

Tuesday, December 13, 2016

8:30 a.m.	Reconvene Meeting	Dr. Wong
8:35 a.m.	Discussion of Response to Charge Questions (Cont'd)	Writing Groups*:
	3b(iii) Points of departure for kidney and other urogenital system endpoints	Drs. Hugh Barton, <u>Jacqueline Hughes-Oliver</u> , <u>Marilyn Morris</u> , Ken Portier, Alan Stern
	3b(iv) Uncertainty factors for kidney other urogenital system endpoints	Drs. <u>Joanne English</u> , <u>Melanie Marty</u> , Alan Stern
	3b(v) Kidney and other urogenital system-specific reference dose	Drs. <u>Maarten Bosland</u> , <u>Lawrence Lash</u> , Thomas Rosol
9:15 a.m.	3c <u>Developmental and reproductive system effects</u>	
	3c(i) Developmental and reproductive system hazard	Drs. <u>Alan Hoberman</u> , Susan Laffan, <u>Marvin Meistrich</u> , Victoria Persky
	3c(ii) Reproductive system-specific Toxicity values	Drs. Alan Hoberman, <u>Susan Laffan</u> , <u>Marvin Meistrich</u>

* Lead discussants are denoted by underlines

	3c(iii) Points of departure for Reproductive system endpoints	Drs. Hugh Barton, <u>Jacqueline Hughes-Oliver</u> , <u>Marilyn Morris</u> , Ken Portier, Stephen Roberts, Alan Stern
10:30 a.m.	Break	
10:45 a.m.	3c(iv) Uncertainty factors for reproductive system endpoints	Drs. Joanne English, <u>Melanie Marty</u> , <u>Alan Stern</u>
	3c(v) Reproductive system-specific Reference dose	Drs. Alan Hoberman, Susan Laffan, <u>Marvin Meistrich</u> , <u>Melanie Marty</u>
	3d. <u>Other noncancer hazards</u>	<u>Drs. James Bruckner</u> , <u>Joanne English</u> , Victoria Persky
12:00 p.m.	Lunch	
1:00 p.m.	3e. <u>Cancer</u>	
	3e(i) Cancer hazard	Drs. Maarten Bosland, George Cobb, <u>Mary Boudreau</u> , <u>David Eastmond</u> , Victoria Persky, <u>Steve Roberts</u> , Thomas Rosol, Robert Turesky
	3e(ii) Cancer-specific toxicity values	Drs. <u>Maarten Bosland</u> , <u>Mary Boudreau</u> , David Eastmond, Steve Roberts, Thomas Rosol
	3e(iii) Points of departure for cancer endpoints	Drs. Jacqueline Hughes-Oliver, Marilyn Morris, <u>Ken Portier</u> , <u>Stephen Roberts</u> , Alan Stern
2:45 p.m.	Break	
	<ul style="list-style-type: none"> • Charge Question #4 – Dose-Response Analysis 	
	4a. Oral reference dose for effects other than cancer	Drs. Jacqueline Hughes-Oliver, Stephen Lasley, Melanie Marty, <u>Ken Portier</u> , <u>Alan Stern</u>

* Lead discussants are denoted by underlines

	4b. Inhalation reference concentration for effects other than cancer	Drs. <u>Hugh Barton</u> , James Bruckner, Marilyn Morris, Victoria Persky, <u>Stephen Roberts</u>
	4c. Oral slope factor for cancer	Drs. Marteen Bosland, Mary Boudreau, Dave Eastman, <u>Jacqueline Hughes-Oliver</u> , <u>Ken Portier</u> , Stephen Roberts, Tom Rosol, Alan Stern
	4d. Inhalation unit risk for cancer	Drs. Hugh Barton, <u>James Bruckner</u> , <u>Marilyn Morris</u> , Stephen Roberts
	• Charge Question #5 – Executive Summary	Drs. <u>Joanne English</u> , <u>Stephen Roberts</u>
4:40 p.m.	Brief Public Clarifying Comments	Registered speakers
5:00 p.m.	Recess	

Wednesday, December 14, 2016

8:30 a.m.	Panel to prepare for slide presentations	Panel Members
9:00 a.m.	Reconvene Meeting	Dr. Wong
	Summary of Responses to Charge Questions #1; 2(a), 2(b), 2(c); 3(a), 3(b), 3(c)	Dr. Ken Ramos, lead discussants and panel members
11:00 a.m.	Break	
11:15 a.m.	Summary of Responses to Charge Questions #3(d), 3(e), #4(a), 4(b), 4(c), 4(d), #5	Dr. Ken Ramos, lead discussants and panel members
12:45 p.m.	Next Steps	Dr. Ramos
1:00 p.m.	Adjourn	Dr. Wong

* Lead discussants are denoted by underlines

* Lead discussants are denoted by underlines